VivoSeq
Cardiovascular

Vascular Dementia

14

Pipeline Programs↗

1

Active Trials↗

11

Companies Involved↗

Vascular Dementia is an emerging landscape with 14 programs across 11 companies. The most active players are Charsire Biotechnology Corp., Sinphar Pharmaceutical Co., Ltd, Mezzion Pharma Co. Ltd. 6 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

92/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Charsire Biotechnology Corp.

1 program

Phase 2S

Sinphar Pharmaceutical Co., Ltd

1 program

Phase 2M

Mezzion Pharma Co. Ltd

1 program

Phase 2Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Phase 3Novartis logo

Novartis

2 programs

Phase 3E

Ever Neuro Pharma GmbH

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

18

clinical trials

Completed12 · 67%
Unknown status4 · 22%
Active, not recruiting1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

18 trials

Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
Active, not recruiting·—·Phase 3·NCT03804229·707 enrolled
Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)
Completed·SSinphar Pharmaceutical Co., Ltd·Phase 2·NCT01475578·240 enrolled
A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia
Completed·CCharsire Biotechnology Corp.·Phase 2·NCT02886494·80 enrolled
Rivastigmine Capsules in Patients With Probable Vascular Dementia
Completed·Novartis logoNovartis·Phase 3·NCT00130338·521 enrolled
Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia
Completed·Eisai logoEisai·Phase 4·NCT00165763·36 enrolled
A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia
Completed·EEver Neuro Pharma GmbH·Phase 4·NCT00947531·242 enrolled
A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00261573·593 enrolled
Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia
Completed·—·Phase 2·NCT01761227·240 enrolled
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
Completed·Novartis logoNovartis·Phase 3·NCT00099216·708 enrolled
Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia
Completed·—·Phase 2·NCT03230071·160 enrolled
A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00035191·254 enrolled
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions
Completed·PPeking University First Hospital·Phase 4·NCT00847860·200 enrolled
Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia
Completed·—·Phase 3·NCT02453932·543 enrolled
BAC in Patient With Alzheimer's Disease or Vascular Dementia
Withdrawn·CCharsire Biotechnology Corp.·Phase 2·NCT02467413
Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia
Unknown status·SSheba Medical Center·Phase 4·NCT00229333·40 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)